ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-OR111

Serum and Urine Biomarkers Related to Renal Fibrosis Predict Renal Outcome in Patients with IgA Nephropathy

Session Information

  • Mostly IgA Nephropathy
    November 07, 2019 | Location: Ballroom C, Walter E. Washington Convention Center
    Abstract Time: 05:06 PM - 05:18 PM

Category: Glomerular Diseases

  • 1201 Glomerular Diseases: Fibrosis and Extracellular Matrix


  • Maixnerova, Dita, Dept. of Nephrology, Prague, Prague, Czechia
  • Sparding, Nadja, Nordic Bioscience , Herlev, Denmark
  • Neprasova, Michaela, General Teaching Hospital in Prague, Dobris, Czechia
  • Bartonova, Lenka, Charles University, Prague, Czech Republic, Prague, Czechia
  • Honsova, Eva, IKEM, Prague, Czechia
  • Hruskova, Zdenka, Department of Nephrology,General University Hospital and First Faculty of Medicine, Charles University, Prague 2, Czechia
  • Suchanek, Miloslav, University of Chemical Technology Prague, Prague, Czechia
  • Tesar, Vladimir, General University Hospital in Prague, Prague, Prague, Czechia
  • Genovese, Federica, Nordic Bioscience , Herlev, Denmark

IgA nephropathy (IgAN), the most common primary glomerulonephritis worldwide, has serious outcomes with end-stage renal disease developing in 30-50% of patients. Clinical predictors such as proteinuria, hematuria, hypertension as well as renal fibrosis may play a role in IgAN onset and/or progression. Here, we assessed serum and urine biomarkers related to renal fibrosis and histological findings in renal-biopsy specimens from patients with IgAN, ANCA associated vasculitis and compared with healthy controls.


We evaluated 46 patients with biopsy-proven IgAN, 45 patients with ANCA associated vasculitis, who were assessed at time of diagnosis for estimated glomerular filtration rate (eGFR), proteinuria, microscopic hematuria, hypertension, then followed prospectively and compared to 9 healthy controls (mean follow-up 51.8 months). Serum and urine samples collected at diagnosis were analyzed for biomarkers related to renal fibrosis using a novel enzyme-linked immunosorbent assay as well as histological evaluation of renal tissues at time of kidney biopsies were assessed. Linear discriminant analysis, logistic regression model and Kaplan-Meier (survival) analysis were used for statistic processing.


We found serum and urine biomarkers such as EGF, PRO-C6, PRO-C3, which correlated with the level of histological fibrosis in kidney biopsies (P<0.05) and exactly predicted renal outcome of patients with IgAN (P<0.05). Moreover, addition of two other biomarkers such as serum LG1M and urine C3M completely differentiated patients with IgAN compared to patients with ANCA associated vasculitis and healthy controls (accuracy of classification 100 %).


In conclusion, serum and urine biomarkers related to renal fibrosis such as EGF, PRO-C6, PRO-C3 predicted renal outcome of patients with IgAN. Future studies are needed to validate these preliminary findings and to determine the power of these urinary and serum markers for assessment of responses to treatment.